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Abstract: OBJECTIVE: To evaluate whether imaging of the trunk could be omitted in patients with
inflammatory myopathies without losing diagnostic accuracy using a restricted whole-body magnetic
resonance imaging (rWB-MRI) protocol. METHODS: After approval by the institutional review board,
this study was performed in 63 patients (male/female, 13/50; median age, 52 years; range, 20-81 years)
with new-onset myopathic symptoms (group 1, n = 41) or previously diagnosed inflammatory myopathy
(group 2, n = 22). After performing whole-body MRI (WB-MRI) at 3.0 Tesla, myositis and fatty
atrophy were evaluated in different muscles by two independent radiologists. The intra-class correlation
coefficient (ICC) was calculated to evaluate inter-observer reliability. RESULTS: Acquisition time was
56:01 minutes for WB-MRI and 37:37 minutes (32.8 % shorter) for rWB-MRI. In group 1, 14 patients
were diagnosed with inflammatory myopathy based on muscle biopsy. rWB-MRI and WB-MRI showed
equal sensitivity (42.9 %) and specificity (100 %) for myositis, and showed equal sensitivity (71.4 %) and
similar specificity (63.0 % and 48.1 %, respectively) for fatty atrophy. No myositis was found in the body
trunk in any patient. Inter-observer reliability was between substantial and perfect (ICC, 0.77-1.00).
CONCLUSIONS: rWB-MRI showed diagnostic accuracy similar to WB-MRI for inflammatory myopathy
at markedly reduced overall acquisition time. KEY POINTS: Whole-body MRI (WB-MRI) is a time-
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Abstract
Objective To evaluate whether imaging of the trunk could be
omitted in patients with inflammatory myopathies without
losing diagnostic accuracy using a restrictedwhole-bodymag-
netic resonance imaging (rWB-MRI) protocol.
Methods After approval by the institutional review board, this
study was performed in 63 patients (male/female, 13/50; me-
dian age, 52 years; range, 20–81 years) with new-onset myo-
pathic symptoms (group 1, n=41) or previously diagnosed
inflammatory myopathy (group 2, n=22). After performing
whole-body MRI (WB-MRI) at 3.0 Tesla, myositis and fatty
atrophy were evaluated in different muscles by two indepen-
dent radiologists. The intra-class correlation coefficient (ICC)
was calculated to evaluate inter-observer reliability.
Results Acquisition timewas 56:01 minutes forWB-MRI and
37:37 minutes (32.8 % shorter) for rWB-MRI. In group 1, 14
patients were diagnosed with inflammatory myopathy based
on muscle biopsy. rWB-MRI and WB-MRI showed equal
sensitivity (42.9 %) and specificity (100 %) for myositis,
and showed equal sensitivity (71.4 %) and similar specificity
(63.0 % and 48.1 %, respectively) for fatty atrophy. No myo-
sitis was found in the body trunk in any patient. Inter-observer
reliability was between substantial and perfect (ICC, 0.77–
1.00).
Conclusions rWB-MRI showed diagnostic accuracy similar
to WB-MRI for inflammatory myopathy at markedly reduced
overall acquisition time.
Key Points
• Whole-body MRI (WB-MRI) is a time-consuming imaging
modality.
• A shortened MRI protocol was evaluated for inflammatory
myopathies.
• The proposed protocol showed diagnostic accuracy similar
to WB-MRI.
Keywords Magnetic resonance imaging .Whole-body .
Inflammatorymyopathy . Polymyositis . Dermatomyositis
Introduction
Magnetic resonance imaging (MRI) is a widely used imaging
modality for the diagnosis and follow-up of muscle changes in
inflammatory myopathies [1–7], which mainly include poly-
myositis and dermatomyositis with specific clinic-serologic
subtypes. Traditionally, MRI focused on selected muscle re-
gions depending on clinically suspected muscle changes [8,
9]. In the past few years, however, the use of whole-bodyMRI
(WB-MRI) has been increasingly propagated because of its
several advantages. For example, this technique allows addi-
tional detection of affected yet clinically “silent” muscle
groups, especially in early disease when muscle strength is
still preserved. Furthermore, the recognition of spatial distri-
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symmetrical yet multifocal—helps to differentiate inflamma-
tory from neurodegenerative muscle disease and can guide
muscle biopsy, with a substantial improvement in diagnostic
accuracy (without MRI, the false-negative biopsy rate has
been found to be up to 45 %) [10]. In patients with an
established diagnosis, WB-MRI helps to distinguish muscle
weakness due to persistent inflammation as opposed to fatty
atrophy, and thus substantially influences therapeutic
decisions.
Current MRI protocols usually include both T1-
weighted and short-tau inversion recovery (STIR) se-
quences in order to assess fatty atrophy and depict muscle
oedema, respectively [1, 2]. Despite technical advances
such as parallel imaging and free table movement [11],
WB-MRI remains time-consuming, and thus uncomfortable
for patients. Total imaging time is typically around 45 mi-
nutes [1, 2, 12], and even longer in the case of additional
contrast-enhanced sequences [2, 13].
There is a general consensus among clinical experts
in the field that in adult patients with myositis, the body
trunk is rarely involved [14, 15]. Hence, we hypothe-
sized that imaging of the trunk could be dropped,
favouring a time-saving restricted WB-MRI (rWB-
MRI) protocol confined to the muscles of the upper
and lower extremities. The purpose of this study was
to evaluate whether imaging of the trunk could be omit-
ted using an rWB-MRI protocol without losing accuracy
in the diagnosis of inflammatory myopathy.
Materials and methods
Study subjects
After approval by the institutional review board, this
prospective study was performed in 63 consecutive
adult patients (male/female, 13/50; median age, 52 years;
range, 20–81 years) who were seen in the rheumatology
division and referred to the department of radiology for
WB-MRI between December 2012 and February 2014.
Patients presented either with new-onset myopathic
symptoms, e.g. myalgia, muscle fatigue, reduced muscle
strength or endurance (group 1, n=41; male/female, 11/
30; median age, 52 years; range, 20–81 years), or for
follow-up visits of established inflammatory myopathy
(group 2, n=22; male/female, 2/20; median age,
53 years; range, 21–77 years). All patients underwent
comprehensive diagnostic workup including clinical as-
sessment, laboratory studies and muscle biopsy. For the
purpose of this study, group 1 was further subdivided
into patients who later were (group 1A) or were not
(group 1B) diagnosed with inflammatory myopathy.
Whole-body MRI
All WB-MRI examinations were performed on a standard
3.0TMR scanner (Magnetom Skyra; Siemens Healthcare, Er-
langen, Germany) using the complete whole-body matrix coil
set (including a 20-channel head/neck coil, a 32-channel spine
coil, two 18-channel body coils and a 36-channel peripheral
coil). Patients were positioned in supine position. The stan-
dard whole-body imaging protocol included six stacks of
STIR sequences in coronal plane (neck, chest, abdomen, pel-
vis, upper and lower legs; chest and abdomen with respiratory
triggering; TR, 3,500–6,000 ms; TE, 257–353 ms; slice thick-
ness, 4 mm; slice gap, 0 mm; in-plane resolution, 1.5×
1.1 mm2; number of averages, 2) as well as six stacks of axial
pre- and post-contrast T1-weighted turbo spin-echo (TSE) se-
quences (TR, 702 ms; TE, 8.7 ms in-phase and 11 ms
opposed-phase; slice thickness, 4 mm; slice gap, 5 mm; in-
plane resolution, 1.4×1.4 mm2; number of averages, 2). The
TSE sequences were acquired using the Dixon technique,
which allowed calculating water-only and fat-only images
out of the in-phase and opposed phase images. The overall
field of view was 180 (longitudinal)×50 (transversal)×40 cm
(sagittal). The total acquisition time for the full whole-body
protocol (WB-MRI) was 56 min, 1 s. Dropping the stacks for
the body trunk (chest and abdomen) reduced the acquisition
time by 18 min, 24 s (32.8 %), resulting in a remaining acqui-
sition time of only 37 min, 37 s.
Image analysis
For all subjects, key muscles (as defined below) were assessed
in terms of myositis and fatty atrophy by two independent
musculoskeletal radiologists (L.F., and A.M., further referred
to as reader 1 [R1] and reader 2 [R2]), who were blinded to
clinical data and laboratory values. Subsequently, a common
readout was performed on muscles scored differently by the
two readers in order to reach consensus. Active myositis was
defined as hyperintense signal abnormality in the muscles on
STIR or water-only images (muscle oedema) with corre-
sponding enhancement on post-contrast fat-suppressed T1-
weighted images. Similar to a previous study [3], active myo-
sitis was scored 0 (none), 1 (focal) or 2 (involving>50 % of
the muscle) in each muscle. Fatty atrophy was also evaluated
in each muscle on the in-phase TSE and fat-only images ac-
cording to the Goutallier classification [16]: 0 (normal, no
fatty streak), 1 (some fatty streaks), 2 (important fatty streaks,
but still more muscle than fat), 3 (as much fat as muscle), or 4
(more fat than muscle). Example images of myositis and fatty
atrophy are provided in Fig. 1.
The total myositis and fatty atrophy scores (i.e. the respec-
tive sums of all values) were then calculated as follows:
Scores for rWB-MRI included the deltoid, rotator cuff, biceps,
triceps, gluteus, quadriceps, adductor, hamstring, and tibialis
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anterior muscles. Scores for WB-MRI also included muscles
of the body trunk, namely the pectorales, trapezius, serratus
anterior, latissimus dorsi, intercostales, erector spinae, abdom-
inal wall, and iliopsoas muscles. Small muscles such as the
neck flexors or muscles in the forearm and feet were not in-
cluded due to limited image resolution and/or field-of-view
coverage.
In addition to the muscle scores, incidental findings in other
organs of the body trunk were assessed by both radiologists
during the consensus reading.
Statistical analysis
All statistical analysis was performed using SPSS software
(version 20; IBM Corp., Armonk, NY, USA). Demographic
data, clinical parameters and muscle scores of the different
groups were compared using multivariate analysis of variance
(ANOVA) and post hoc analysis with Fisher’s least significant
difference (LSD) test; a p value of<0.05 indicated significant
differences.
Inter-observer agreement was evaluated by calculating
intra-class correlation coefficients (ICCs). An ICC value of
0.21–0.40 was interpreted as fair agreement, 0.41–0.60 as
moderate agreement, 0.61–0.80 as good agreement, 0.81–
0.99 as almost perfect agreement, and 1.00 as perfect agree-
ment [17].
Total myositis and fatty atrophy scores for the different
groups were compared between rWB-MRI and WB-MRI
using Student’s paired t tests with Bonferroni correction.
For groups 1A (inflammatory myopathy) and 1B (no in-
flammatory myopathy, i.e. negative controls), sensitivity and
specificity of the myositis and fatty atrophy scores were
Fig. 1 Whole-body MR images
of a 35-year-old female patient
diagnosed with polymyositis
5 months prior and treated with
prednisone and methotrexate
(included in group 2). No muscle
abnormalities were present in the
body trunk. Left: Coronal whole-
body STIR image automatically
generated from six separate
stacks. Right: Top: Coronal STIR
image showing oedema (arrow)
in the quadriceps muscle on the
right side. Middle and bottom:
Axial TSE images (in-phase)
illustrating bilateral fatty atrophy
(arrowheads) in the gluteus
medius, erector spinae and
hamstring muscles
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calculated in both WB-MRI and rWB-MRI based on the final
consensus readout. The area under the receiver operating char-
acteristic (ROC) curve was calculated to evaluate the diagnos-
tic accuracy of the respective scores. An area under the curve
of 0.70–0.79 was considered to indicate a fair test and 0.51–
0.69 was considered to indicate a poor test for discriminating
between patients with and without inflammatory myopathy
[18]. For group 2, WB-MRI and rWB-MRI were compared
in terms of the myositis and fatty atrophy scores only; sensi-
tivity and specificity were not calculated, since these patients
were already diagnosed with and treated for inflammatory
myopathy.
Since fatty atrophy of the erector spinae muscle was a com-
mon finding in all groups (see below), its correlation with age
and time since diagnosis was assessed by calculating
Kendall’s correlation coefficient (τ).
Results
Demographical and clinical data
Of the 41 patients with new-onset myopathic symptoms
(group 1), 14 were subsequently diagnosed with inflammatory
myopathy (group 1A), whereas no inflammatory myopathy
was diagnosed in the other 27 patients (group 1B). The pa-
tients in group 2 had been previously diagnosed with inflam-
matory myopathy and received follow-up imaging for control
of treatment response.
No significant differences with regard to age, creatinine
phosphokinase (CPK), C-reactive protein (CRP) or lactate
dehydrogenase (LDH) were found among the three patient
groups (group 1A vs. group 1B: p values 0.06–0.35; group
1A vs. group 2: p-values 0.32–0.93; group 1B vs. group 2:
p values 0.10–0.39). The CPK was markedly elevated (1,
418 IU/L, normal<167 IU/L) in one outlier patient in group
2 with severe immune-mediated necrotizing myositis, which
is a common and typical phenomenon in those patients; the
CPK in the other patients of group 2 was in the range of 33–
535 IU/L (Table 1).
Comparison of muscle scores among patient groups
Inter-observer reliability was “almost perfect” to “perfect” for
myositis (ICC, 0.89–1.00) and “substantial” to “almost per-
fect” for fatty atrophy (ICC, 0.77–0.97). Table 2 provides the
respective values of total myositis and fatty atrophy scores for
WB-MRI and rWB-MRI. In both WB-MRI and rWB-MRI,
the myositis score was significantly higher in group 1A than
group 1B (WB-MRI: p<0.001; rWB-MRI: p<0.001). Fur-
thermore, the myositis score was higher in group 2 than group
1A (WB-MRI: p=0.026; rWB-MRI: p=0.025) and 1B (WB-
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highest fatty atrophy scores; however, there was no significant
difference in scores among the groups (WB-MRI: p values=
0.22-0.92; rWB-MRI: p values=0.17-0.44).
In both groups 1A and 2, the quadriceps muscles showed
the highest myositis scores (0.57±0.62 and 0.55±0.78, re-
spectively), underscoring the predominant affection of proxi-
mal muscles, especially of the lower extremities. Patients with
new-onset inflammatory myopathy showed myositis mainly
in the quadriceps muscles, whereas those with established
disease and longer disease duration also showed involvement
of the pelvic girdle. No myositis was found in the muscles of
the body trunk in any patient (Fig. 2).
The most common finding in the trunk in all patient groups
was fatty atrophy of the erector spinae muscle at the lumbar
level, which was present in 40 patients (63.5 %), with a
resulting score for muscle atrophy of 0.98±0.99 (mean±stan-
dard deviation). This finding, which is commonly related to
age-related degeneration and hyperlordosis [19, 20], was not
significantly higher in any patient group compared to the other
groups (p -values=0.31–0.58); it showed a weakly positive
correlation with age (Kendall’s correlation coefficient τ,
0.33, p=0.02), but no significant correlation with time since
diagnosis or since initial presentation (τ -0.01, p=0.96). Pa-
tients in group 2 who did not receive drug treatment (n=5)
showed only mild fatty atrophy of the lumbar erector spinae
muscle.
WB-MRI vs. rWB-MRI
Because no myositis was found in the body trunk of any
patient, the total myositis scores in WB-MRI and rWB-MRI
were equal. The total fatty atrophy scores were significantly
higher in WB-MRI than rWB-MRI in all groups (group 1A,
p=0.005; group 1B, p=0.009; group 2. p<0.001), which is
largely explained by the frequent involvement of the erector
spinae muscle (see above) (Fig. 2).
The performance of rWB-MRI and WB-MRI for the
diagnosis of myositis in our population was identical
(sensitivity, 42.9 %; specificity 100 %; positive predic-
tive value, 100 %; negative predictive value, 77.1 %).
For fatty atrophy, the sensitivity was equal in rWB-MRI
and WB-MRI (71.4 % and 71.4 %, respectively), but
the specificity was even higher in rWB-MRI than WB-
MRI (63.0 % vs. 48.1 %, respectively). The area under
the ROC curve of the myositis score was equal in both
rWB-MRI and WB-MRI (0.714) and, according to the
aforementioned interpretation, indicated “fair” test accu-
racy. The area under the ROC curve for fatty atrophy
score was 0.598 for WB-MRI and 0.672 for rWB-MRI,
corresponding to “poor” test accuracy. This means that
the myositis score allowed “fair” discrimination between
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whereas the fatty atrophy score allowed “poor” discrim-
ination between them.
Incidental findings in the body trunk
Incidental findings in the chest included cardiomegaly (n=1),
a vertebral hemangioma (n=1), multinodular goiter (n=2),
and a cystic lesion in the posterior mediastinum (n=1), which
was interpreted as a lymphogenic cyst on a dedicated chest CT
7 days later. In the abdomen, findings included single or mul-
tiple liver cysts (n=8), liver hemangiomas (n=3), renal cysts
(n=12), diverticulosis of the sigmoid colon (n=5), gallstones
(n=3), uterine fibroids (n=4) and cystic adnexal masses (n=6)
(Fig. 3). One patient had a hip prosthesis, which did not affect
muscle assessment.
Discussion
The present study compared diagnostic accuracy between a
restrictedWB-MRI (rWB-MRI) and a conventionalWB-MRI
protocol in adult patients with either clinically suspected or
previously diagnosed inflammatory myopathy. Results
showed that the accuracy of rWB-MRI was almost equal to
that of conventional WB-MRI for the diagnosis of new-onset
inflammatory myopathy or in follow-up examinations.
Fig. 2 Myositis (range 0–2) and fatty atrophy (range 0–4) in key muscles
included in the whole-body magnetic resonance imaging (WB-MRI) and
restricted WB-MRI (rWB-MRI) assessments, respectively, of the
different patient groups (1A, 1B, 2). Data are presented as mean values
(bars) with standard deviation (whiskers), and are obtained from the
consensus readouts of two radiologists. For better visibility, data from
the right and left side of the body are merged
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Polymyositis, dermatomyositis and myopathy associated
with systemic sclerosis typically involve the shoulder girdle
and pelvic girdle, including the proximal extremities, and
muscle changes are readily seen on WB-MRI [21, 22]. The
observations in the present study agree with those in the liter-
ature: in new-onset inflammatory myopathy, the quadriceps
muscles were most frequently involved, whereas in long-
standing disease, other muscles of the proximal extremities
were also involved. This additional involvement of other mus-
cle groups explains the higher myositis score in patients with
long-standing disease (group 2) compared to those with recent
diagnosis (group 1A).
None of the assessed muscles of the body trunk in any of
the patients were found to be affected by myositis. This find-
ing confirms the rarity of involvement of the body trunk in
patients with inflammatory myopathies [23]. In contrast to
adult forms of inflammatory myopathies, juvenile dermato-
myositis (JDM) has been reported to show a high prevalence
of muscle changes in the abdominal wall (56 %) and psoas
muscles (54 %) seen in WB-MRI [3]. Other rare systemic
diseases that involve thoracic and abdominal muscles include
muscle dystrophies, neuromuscular diseases, and glycogen
storage diseases [21, 24–27]. However, these entities com-
monly present in childhood, where WB-MRI may be per-
formed only under general anaesthesia. In addition, the role
of WB-MRI in these disorders has yet to be clarified. Patients
with inflammatory myopathies have a substantially increased
risk for malignancies compared to the general population [28,
29]. Dermatomyositis is associated with lung, gastric, pancre-
atic, colorectal, and ovarian cancers [30], whereas polymyo-
sitis is associated with non-Hodgkin lymphoma, lung cancer
and bladder cancer [30]. Cancer screening is usually
performed with computed tomography of the chest and abdo-
men, gynaecological and urological examination, and blood
analysis. There are no official guidelines recommending WB-
MRI as a cancer screening tool in inflammatory myopathies,
particularly not a protocol dedicated to the detection of myo-
sitis, which for example does not include diffusion-weighted
imaging. No malignant disease was discovered in the present
study. Even without abdominal imaging in an rWB-MRI pro-
tocol, the pelvic organs (and thus incidental findings such as
adnexal masses) are still covered on the images of the pelvis
(Fig. 3). Therefore, in our view, the purported higher inci-
dence of malignancies in these patients does not preclude
using an rWB-MRI protocol. Systemic muscle diseases, main-
ly polymyositis, frequently involve the heart muscle [31];
however, cardiac imaging requires a dedicated protocol, and
the heart cannot be reliably assessed with current WB-MRI
methods.
MRI has proven useful for detecting muscle changes and
for differentiating acute inflammation (myositis) from chronic
damage (fatty atrophy). MR protocols in suspected myopathy
should include both STIR images to depict muscle oedema
and T1-weighted images to assess fatty atrophy [1, 2]. Fur-
thermore, images should be acquired in both axial and coronal
orientation for the detection of heterogeneous and multifocal
involvement within individual muscles [12, 27]. Imaging pa-
rameters of theWB-MRI protocol in the present study, includ-
ing repetition time, echo time, and slice thickness, were com-
parable to those in other protocols reported in the literature
[21, 32]. Our protocol also included contrast-enhanced axial
TSE images, the benefit of which in inflammatory myopathies
is controversial [2, 13]. In our WB-MRI protocol, almost the
same amount of time could have been saved by renouncing
Fig. 3 Axial pre- (top left) and
post-contrast (top right) T1-
weighted images and coronal
STIR images (bottom) of a 57-
year old female patient from
group 2 diagnosed with
polymyositis. Note the subtle
hyperintensities in the gluteus
maximus muscles bilaterally on
STIR, which are confirmed as




finding of a right-sided cystic
ovarian mass (arrowheads) could
be classified as benign
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the contrast-enhanced images instead of using rWB-MRI
(18:30 min and 18:24 min, respectively). However, we found
them indispensable for confirmation of suspected muscle in-
flammation, to differentiate inflammatory myopathy from oth-
er forms of myopathy (such as neurodegenerative or metabol-
ic disease), and for further characterization of incidental find-
ings, e.g. cystic ovarian masses (Fig. 3).
Our study has several limitations. First, it is a retrospective
study with an inherent bias regarding the inclusion of study
subjects. The patients showed rather low myositis scores,
which may be explained with the early time of diagnosis
and/or therapeutic success. Given the low myositis scores,
the ROC analyses should be interpreted with caution. In a
larger, more general patient population, the performance of
the myositis score may be different (e.g. higher) in both
WB-MRI and rWB-MRI. Second, the observation period of
this study does not principally rule out false-negative cases;
however, to date, none of the patients in group 1B have been
diagnosed with inflammatory myopathy. Lastly, the rWB-
MRI protocol was virtually obtained by dropping the images
of the chest and abdomen. A real rWB-MRI protocol, howev-
er, could have been optimized for image resolution or signal-
to-noise ratio in the remaining stacks while maintaining some
gain in time over a regular WB-MRI protocol. Thus the saved
time could be used, at least in part, to improve other imaging
aspects.
In conclusion, whole-body MRI restricted to the proximal
extremities—with omission of the body trunk—shows similar
accuracy for diagnosis and follow-up of patients with inflam-
matory myopathy.
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